Vaccitech
$5
11
+$0.51+11.36% Monday 22:00
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
186.48M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Earnings
13MayExpected
Expected EPS
-0.54
Actual EPS
-0.4
Financials
69.37%Profit Margin
Profitable38.25MRevenue
26.53MNet Income
Analyst Ratings
$4.00Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow VACC. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Gilead Sciences
GILD
Mkt Cap148.78B
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
AMGEN
AMGN
Mkt Cap160.66B
Biogen
BIIB
Mkt Cap22.63B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
About
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
Show more...
CEO
Employees
49
Country
US
ISIN
US91864C1071
WKN
000A3CN5Q
Listings
0 Comments
Share your thoughts
FAQ
What is Vaccitech stock price today?▼
The current price of VACC is $5 USD — it has increased by +11.36% in the past 24 hours. Watch Vaccitech stock price performance more closely on the chart.
What is Vaccitech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaccitech stocks are traded under the ticker VACC.
What is Vaccitech market cap?▼
Today Vaccitech has the market capitalization of 186.48M
What were Vaccitech earnings last quarter?▼
VACC earnings for the last quarter are 0 USD per share, whereas the estimation was -0.57 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaccitech revenue for the last year?▼
Vaccitech revenue for the last year amounts to 38.25M USD.
What is Vaccitech net income for the last year?▼
VACC net income for the last year is 26.53M USD.
How many employees does Vaccitech have?▼
As of April 04, 2026, the company has 49 employees.
In which sector is Vaccitech located?▼
Vaccitech operates in the Professional, Scientific, and Technical Services sector.
When did Vaccitech complete a stock split?▼
Vaccitech has not had any recent stock splits.